Patents Assigned to MEDIGEN, INC.
-
Publication number: 20250057932Abstract: Compositions for protecting subjects from diseases caused by (+)SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+)SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+)SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.Type: ApplicationFiled: November 4, 2024Publication date: February 20, 2025Applicant: Medigen, Inc.Inventors: Peter Pushko, Irina Tretyakova
-
Patent number: 11576965Abstract: Described herein, are Bovine immunodeficiency virus gag protein (“Bgag”) recombinant virus like particles (“VLPs”) including one or more different types of target pathogen proteins. Also described, are compositions including the Bgag VLPs and the methods of making and using the novel Bgag VLP.Type: GrantFiled: July 1, 2016Date of Patent: February 14, 2023Assignee: MEDIGEN, INC.Inventors: Peter Pushko, Irina Tretyakova
-
Publication number: 20210322535Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.Type: ApplicationFiled: June 24, 2021Publication date: October 21, 2021Applicant: Medigen, Inc.Inventors: Peter Pushko, Irina Tretyakova
-
Patent number: 11058759Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.Type: GrantFiled: November 21, 2017Date of Patent: July 13, 2021Assignee: Medigen, Inc.Inventors: Peter Pushko, Irina Tretyakova
-
Patent number: 10653769Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: GrantFiled: April 19, 2018Date of Patent: May 19, 2020Assignee: MEDIGEN, INC.Inventors: Peter Pushko, Igor Lukashevich
-
Publication number: 20190314482Abstract: Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.Type: ApplicationFiled: November 21, 2017Publication date: October 17, 2019Applicant: Medigen, Inc.Inventors: Peter Pushko, Irina Tretyakova
-
Patent number: 9968672Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: GrantFiled: January 30, 2014Date of Patent: May 15, 2018Assignee: MEDIGEN, INC.Inventors: Peter Pushko, Igor Lukashevich
-
Patent number: 9694065Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: GrantFiled: July 2, 2015Date of Patent: July 4, 2017Assignee: MEDIGEN, INC.Inventors: Peter Pushko, Irina Tretyakova, Igor Lukashevich
-
Patent number: 9101572Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: GrantFiled: January 3, 2011Date of Patent: August 11, 2015Assignee: MEDIGEN, INC.Inventors: Peter Pushko, Irina Tretyakova, Igor Lukashevich
-
Patent number: 8691563Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: GrantFiled: July 17, 2009Date of Patent: April 8, 2014Assignee: Medigen, Inc.Inventors: Peter Pushko, Igor Lukashevich
-
Publication number: 20130052225Abstract: Described herein are i-DNA™ vectors and vaccines and methods for using the same. The i-DNA™ generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly chikungunya virus (CHIKV). When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: ApplicationFiled: January 3, 2011Publication date: February 28, 2013Applicant: MEDIGEN, INC.Inventors: Peter Pushko, Irina Tretyakova, Igor Lukashevich
-
Publication number: 20110243989Abstract: Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.Type: ApplicationFiled: July 17, 2009Publication date: October 6, 2011Applicant: MEDIGEN, INC.Inventors: Peter Pushko, Igor Lukashevich